Lysergic acid diethylamide : a drug of ‘use’ ? Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen and Somnath Mondal Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3), 214–228 DOI: 10.1177/2045125316640440 Abstract : Lysergic acid diethylamide (LSD), described as a classical hallucinogen, began its journey from the middle of the last century following an accidental discovery. Since then, it was used as a popular and notorious substance of abuse in various parts of the world. Its beneficial role as an adjunct to psychotherapy was much unknown, until some ‘benevolent’ experiments were carried out over time to explore some of its potential uses. But, many [...]
Lire la suitePrevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness Receiving Treatment for Alcohol Use Disorders Jordan Skalisky, Emily Leickly, Oladunni Oluwoye, Sterling M. McPherson, Debra Srebnik, John M. Roll, Richard K. Ries, and Michael G. McDonell Cannabis and Cannabinoid Research, 2017, 2, (1), 133-138 DOI: 10.1089/can.2017.0006 Abstract Introduction : People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders (AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates, and impact of cannabis use on those with SMI [...]
Lire la suiteBrain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans : Evidence from Studies of Adult Users. Aviv Weinstein, Abigail Livny, Abraham Weizman. Current Pharmaceutical Design, 2016, 22, 42, 6366-6379. doi: 10.2174/1381612822666160822151323. PMID : 27549374 Abstract Cannabis is the most widely used illicit drug worldwide. Regular cannabis use has been associated with a range of acute and chronic mental health problems, such as anxiety, depression, psychotic symptoms and neurocognitive impairments and their neural mechanisms need to be examined. This review summarizes and critically evaluates brain-imaging studies of cannabis in recreational and regular cannabis users between January 2000 and January 2016. The [...]
Lire la suiteCannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience Sagnik Bhattacharyya, Irina Falkenberg, Rocio Martin-Santos, Zerrin Atakan1, Jose A Crippa, Vincent Giampietro, Mick Brammer and Philip McGuire Neuropsychopharmacology, 2015, 40, 1343–1352 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org doi:10.1038/npp.2014.258 Abstract There is now considerable evidence to support the hypothesis that psychotic symptoms are the result of abnormal salience attribution, and that the attribution of salience is largely mediated through the prefrontal cortex, the striatum, and the hippocampus. Although these areas show differential activation under the influence of delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD), the two major derivatives of cannabis sativa, little is known about [...]
Lire la suiteMarijuana and the Cannabinoids Edited by Mahmoud A. ElSohly, PhD, Humana Press, Totowa, New Jersey, USA, 2007 www.humanapress.com 1. Cannabinoids. I. ElSohly, Mahmoud A. II. Series. [DNLM: 1. Cannabinoids. 2. Cannabis. QV 77.7 M33515 2006] QP801.C27M355 2006 615'.7827--dc22 333 pages, Preface Although primarily used today as one of the most prevalent illicit leisure drugs, the use of Cannabis sativa L., commonly referred to as marijuana, for medicinal purposes has been reported for more than 5000 years. Marijuana use has been shown to create numerous health problems, and, consequently, the expanding use beyond medical purposes into recreational use (abuse) resulted in control of the drug through international treaties. Much research has been [...]
Lire la suiteUsage médical du cannabis et des cannabinoïdes Questions et réponses à l’intention des décideurs politiques Observatoire européen des drogues et des toxicomanies (2019), Office des publications de l’Union européenne, Luxembourg Décembre 2018 PDF ISBN 978-92-9497-406-8 doi:10.2810/25727 TD-06-18-186-FR-N Table des matières : 5 Introduction 6 Quels sont les sujets abordés dans ce rapport? 7 Qu’entend-on par usage médical de cannabis et de cannabinoïdes? 11 PARTIE 1 Quelles données scientifiques attestent-elles d’un usage médical du cannabis et des cannabinoïdes? 11 Comment évaluer l’efficacité des médicaments? 12 Quels sont les données scientifiques récentes de l’efficacité du cannabis et des cannabinoïdes en tant que médicaments? 15 Quels sont les risques pour la santé associés à l’usage médical du [...]
Lire la suiteCannabis Use in Pregnancy. A Tale of 2 Concerns Michael Silverstein, MD, MPH1,2; Elizabeth A. Howell, MD, MPH3; Barry Zuckerman, MD1 JAMA. Published online June 18, 2019. doi:10.1001/jama.2019.8860 Original Investigation Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes Daniel J. Corsi, PhD; Laura Walsh, MSc; Deborah Weiss, PhD; Helen Hsu, MD; Darine El-Chaar, MD; Steven Hawken, PhD; Deshayne B. Fell, PhD; Mark Walker, MD Research Letter Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States Nora D. Volkow, MD; Beth Han, MD, PhD, MPH; Wilson M. Compton, MD, MPE; Elinore F. McCance-Katz, MD, PhD Full Text, https://jamanetwork.com/journals/jama/article-abstract/2736581 In an article in JAMA, Corsi and colleagues1 present the results of a retrospective cohort study of 661 617 women designed to assess associations between maternal cannabis use during pregnancy and adverse obstetrical and [...]
Lire la suiteAssociation Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes Daniel J. Corsi, PhD; LauraWalsh, MSc; DeborahWeiss, PhD; Helen Hsu, MD; Darine El-Chaar, MD; Steven Hawken, PhD; Deshayne B. Fell, PhD; MarkWalker,MD JAMA, Published online June 18, 2019. doi:10.1001/jama.2019.8734 Key Points Question Is there an association between prenatal cannabis exposure and maternal, perinatal, and neonatal outcomes? Findings In this retrospective cohort study that included 661 617 pregnancies and 9427 reported cannabis users, the rate of preterm birth among reported cannabis users was 12% vs 6% in nonusers, a statistically significant difference. Meaning Reported cannabis use in pregnancy was associated with significant increases in the rate of preterm [...]
Lire la suiteADDICTIONS & troubles psychiatriques, REPERES Fédération Addiction, mai 2019 Avant-Propos L’association entre les pathologies addictives et psychiatriques est une source majeure de préoccupation et de difficultés pour les professionnels et les équipes des deux champs mais aussi et avant tout pour les personnes concernées et leur entourage, avec une qualité de vie fortement altérée. Ces comorbidités, ces pathologies associées ou duelles, selon les qualifications, sont en effet difficiles à repérer et à prendre en charge, chaque filière de soins, psychiatrique ou addictologique, ayant tendance à concentrer son attention et ses interventions sur la pathologie de son domaine d’expertise. Leur pronostic est péjoratif, l’évolution [...]
Lire la suiteThe Cannabis Conundrum : Thinking Outside the THC Box Sarah L. Hagerty, Sophie L. York Williams, Vijay A. Mittal, and Kent E. Hutchison The Journal of Clinical Pharmacology, 2015, 55, 8, 839–841 DOI: 10.1002/jcph.511 Keywords : cannabis, cannabinoids, D9-tetrahydrocannabinol (THC), cannabidiol (CBD), psychosis Despite nationwide movements to legalize and regulate cannabis, our understanding of its effects on human health is tenuous at best. Developing a solid evidence base regarding the health effects of cannabis is imperative given the momentum for legalization and the demand for sound regulatory practices. This present commentary will identify limitations with respect to previous research on cannabis, discuss the genesis and implications [...]
Lire la suite